Citation: Karen E. Livermore, Jennifer Munkley, David J. Elliott. Androgen receptor and prostate cancer[J]. AIMS Molecular Science, 2016, 3(2): 280-299. doi: 10.3934/molsci.2016.2.280
[1] | Reginald Umunakwe, Ifeoma Janefrances Umunakwe, Uzoma Samuel Nwigwe, Wilson Uzochukwu Eze, Akinlabi Oyetunji . Review on properties of hybrid aluminum–ceramics/fly ash composites. AIMS Materials Science, 2020, 7(6): 859-870. doi: 10.3934/matersci.2020.6.859 |
[2] | Marek Konieczny . Mechanical properties and wear characterization of Al-Mg composites synthesized at different temperatures. AIMS Materials Science, 2024, 11(2): 309-322. doi: 10.3934/matersci.2024017 |
[3] | R. Daulath Banu, R. Karunanithi, S. Sivasankaran, B. Subramanian, Abdullah A. Alhomidan . Influence of graphene nanoplatelets (GNPs) and aluminum-carbon layered double hydroxides (Al-C LDH) in polypropylene matrix of hybrid composite structures on the microstructure and mechanical performances. AIMS Materials Science, 2024, 11(5): 882-917. doi: 10.3934/matersci.2024043 |
[4] | Neerajkumar Wayzode, Vinod Suryawanshi . Mechanical properties of graphene nanoplatelets reinforced glass/epoxy composites manufactured using resin film infusion process. AIMS Materials Science, 2023, 10(4): 693-709. doi: 10.3934/matersci.2023038 |
[5] | Abdulkader A. Annaz, Saif S. Irhayyim, Mohanad L. Hamada, Hashim Sh. Hammood . Comparative study of mechanical performance between Al–Graphite and Cu–Graphite self-lubricating composites reinforced by nano-Ag particles. AIMS Materials Science, 2020, 7(5): 534-551. doi: 10.3934/matersci.2020.5.534 |
[6] | Marek Konieczny . Transformation superplasticity of laminated CuAl10Fe3Mn2 bronze-intermetallics composites. AIMS Materials Science, 2020, 7(3): 312-322. doi: 10.3934/matersci.2020.3.312 |
[7] | Afsaneh Dorri Moghadam, J.B. Ferguson, Benjamin F. Schultz, Pradeep K. Rohatgi . In-situ reactions in hybrid aluminum alloy composites during incorporating silica sand in aluminum alloy melts. AIMS Materials Science, 2016, 3(3): 954-964. doi: 10.3934/matersci.2016.3.954 |
[8] | Mohammad Na'aim Abd Rahim, Mohd Shukor Salleh, Saifudin Hafiz Yahaya, Sivarao Subramonian, Azrin Hani Abdul Rashid, Syarifah Nur Aqida Syed Ahmad, Salah Salman Al-Zubaidi . Microstructural investigation and mechanical properties of Al2O3-MWCNTs reinforced aluminium composite. AIMS Materials Science, 2025, 12(2): 318-335. doi: 10.3934/matersci.2025017 |
[9] | Omar Hassan Mahmood, Mustafa Sh. Aljanabi, Farouk M. Mahdi . Effect of Cu nanoparticles on microhardness and physical properties of aluminum matrix composite prepared by PM. AIMS Materials Science, 2025, 12(2): 245-257. doi: 10.3934/matersci.2025013 |
[10] | Ruaa Al-Mezrakchi, Ahmed Al-Ramthan, Shah Alam . Designing and modeling new generation of advanced hybrid composite sandwich structure armors for ballistic threats in defense applications. AIMS Materials Science, 2020, 7(5): 608-631. doi: 10.3934/matersci.2020.5.608 |
Attributed to the strong sp2 C-C bonds, graphene possesses superior mechanical properties such as high elastic modulus (1TPa) and fracture strength (125GPa) [1,2], and is considered taking advantages over carbon nanotube in terms of enhancing materials as reinforcements in composites because of its two-dimensional morphology that favors load transfer and preventing atomic diffusion at elevated temperatures. Consequently, extensive investigations (e.g., [3,4,5,6,7]) have been performed on the use of graphene to strengthen polymers, ceramics and metals. Inclusion of graphene into composites is either through in-situ synthesis [8] or via adding graphene nanoflakes or graphene oxides (GO) [9,10,11,12,13]. Comparatively, GNFs, which is composed of multiple layers of graphene and has similar properties as single-layered one, is more suitable than in-situ synthesis for producing bulk composites and outperforms GO which induces considerable structural defects [14].
Aluminum (Al) matrix composites are lightweight materials that have great potential for applications in automobile, aeronautical and aerospace industries [15,16]. With successful applications of GNFs to strengthen polymers and ceramics [17,18], there have been investigations on the incorporation of GNFs to improve the properties of aluminum, although the challenge is evident due to the significant differences in density between GNFs and aluminum as well as the high processing temperatures. While density differences give rise to difficulties for distributing GNFs relatively uniform in Al matrix, potentially leading to poorly-dispersed GNFs acting as defect sites, the high processing temperature causes unfavorable chemical reactions such as the transformation of GNFs to carbides that would undermine the role of GNFs as reinforcements [19]. The recent processing technologies, though exhibiting differences in specific routes, tend to employ powder metallurgy to fabricate Al-GNFs composites [19,6,20,21], and this has led to significant improvements in composite yield strength. However, existing investigations generally examined quasi-static properties of composites manufactured, and the dynamic behavior, which is critically important for practical applications, was usually overlooked. As dynamic loading introduces transient stress wave and noticeable temperature rise that potentially trigger deformation and fracture mechanisms [22,23,24] distinct from those associate with static loading, a study of material dynamic behavior is necessary to assess the capability of materials to fulfil a variety of demand under various rates of load and the effectiveness of material processing technology.
The present work investigated the behavior of GNFs-reinforced Al composites under various strain rates and attempted to elucidate the mechanisms regarding the effects of strain rate and GNFs on deformation behavior of the composites. The knowledge acquired from the present work lays foundation for design of Al-GNFs composites aiming to sustain load of various rates in complex serving environment.
The components of composites include Al matrix with 1.5wt.%Mg and 3.9wt.%Cu, silicon carbide and GNFs. Al alloy powders were prepared by means of close coupled gas atomization in the atmosphere of nitrogen and the diameter of Al alloy powder obtained was less than 50 µm. GNFs were converted from graphene oxides of a few atomic layers by hydrazine hydrate, and the size of SiC is around 5µm. The weight percentages of GNFs and SiC within composites were respectively 1% and 10%. Synthesis of composites takes four main steps: firstly, powders of all components were mixed and ball milled; secondly, the mixture was processed by hot isostatic pressing, producing consolidated rod; thirdly, hot extrusion was applied to the rod; finally, the extruded rod was solution treated, followed by water quenching. Detailed processing parameters regarding the four steps can be found in Ref. [20].
Stress-strain behavior of the composites were examined at various strain rates, and for each strain rate, three specimens were used. Quasi-static behavior of the composites was tested using Instron Universal Testing machine, according to ASTM standard E9-89a. Specimens were 5 mm in diameter and 4 mm in thickness. The planar surfaces of specimens were polished and molybdenum disulphide grease was applied to reduce the friction between contact surfaces of specimens and the machine.
Dynamic stress-strain behavior was determined via split Hopkinson Pressure Bar (SHPB) system, of which the striker, incident and transmission bars were made of steel and 13mm in diameter. During each test, the specimen, with the same size as quasi-static sample, was sandwiched between incident and transmission bars, and then strikers were propelled by pressurized nitrogen to induce deformation to specimens. Strain gauges were mounted respectively to incident and transmission bars to measure the corresponding amount of strain, denoted by εi and εt. Figure 1 is an example of the signals recorded for stress waves along incident and transmission bars, and the engineering strain rate (${{\dot \varepsilon }_S}$), strain (εS) and stress (σS) for specimens were calculated by Eq 1 [25].
$
˙εS=2c0LS(εi−εt),εS=2c0LSt∫0(εi−εt)dt,σS=AEεtAS.
$
|
(1) |
where c0, A and E represent the stress wave velocity, cross-sectional area and Young's modulus regarding the incident bar; AS and LS stand for the cross-sectional area and initial thickness of the specimen; t denotes elapse of time during an impact event.
In order to achieve a variety of strain rates for specimens, the length and initial velocity of strikers were adjusted, and true strain (εSt) and true stress (sSt) for specimens were determined by Eq 2.
$
εtS=ln(1+εS),σtS=(1+εS)σS
$
|
(2) |
The Vickers micro-hardness of deformed samples was measured using a Matsuzawa MXT50 micro-hardness tester. An indentation load of 50 gf was applied and maintained for 15 seconds. Care was taken to ensure that the diagonal length of each indentation was no larger than 1/5 the sample size, and that all indentations were sufficiently far from each other, as well as from the sample edges.
A JEOL scanning electron microscopy (SEM) equipped with an energy-dispersive X-ray spectroscopy (EDX) was employed to examine the microstructure of specimens, which were polished before subjected to microstructure characterization.
GNFs-reinforced Al Composites versus Unreinforced Al.
Figure 2a shows the stress-strain responses of GNFs-reinforced composites under various strain rates. It is observed that dynamic strength of the composites is significantly higher than the static strength. With an increase in strain rate, composite yield strength tends to increase, but this trend is insignificant for dynamic loading. A noticeable feature is the decrease in stress after reaching the maxima, indicating a weakened strain hardening rates as compared with conventional metallic materials such as copper [22]. As a reference, Figure 2b displays the stress-strain behavior of unreinforced alloys. Similar to the composites, unreinforced alloys exhibit a rise in flow stress with strain rate, but seems to be more sensitive to the change in strain rate, particularly for dynamic loading. Moreover, strain hardening is obviously demonstrated at all strain rates by unreinforced alloy, although the strength is considerably lower than the composite counterpart. It is thus concluded that the incorporation of GNFs can effectively strength aluminum, but meanwhile leads to weakened strain hardening and declined sensitivity to strain rate at high strain rates.
The strengthening effects of GNFs is manifested by Figure 3, which shows that an addition of GNFs leads to an increase in 0.2% offset yield strength (denoted by σY), by around 300 MPa, regardless of the magnitude of strain rates (${\dot \varepsilon }$). According to the earlier study [26], 10 wt.% of SiC caused an increase in Al yield strength by only about 100 MPa. Hence, 100–200 MPa enhancement of the present composite strength was connected with the addition of GNFs. Although the yield strength for GNFs-reinforced composites shows a decline when strain rate exceeds 3000/s, it remains significantly higher than that for unreinforced Al at similar strain rate. Note in Figure 2a that the maximum strength of reinforced Al at strain rate of 3800/s outnumbers those at lower strain rates; hence, the slight decrease in yield strength in Figure 3 does not negate the enhancing effects of GNFs.
Figure 4 shows the distribution of GNFs within the fabricated composites. The darker regions correspond to GNFs in the form of graphene agglomerates, as evidenced by the EDX data. GNFs are either close to equiaxed or elongated in geometry and the border with Al matrix is irregularly shaped. As the interfacial bonding is sufficiently strong for the present processing approach [20], load transfer plays an important role in strengthening Al, due to the high strength of GNFs. The increase in composite yield strength resulting from load transfer can be calculated by Eq 3 [12], where pr and fr represent aspect ratio and volume fraction of GNFs and σAl denotes the yield strength of Al matrix. Eq 3 suggests that enhancement of yield strength increases with volume or weight fraction of GNFs, and this is consistent with the present and existing investigations [6], for which weight percentages of GNFs are respectively 1% and 0.3%, corresponding to increments of yield strengths by 300 MPa and 95 MPa.
$ \Delta {{\rm{ \mathsf{ σ} }}_{LT}} = {p_r}{f_r}{{\rm{ \mathsf{ σ} }}_{Al}} $ | (3) |
Figure 5 illustrates the feature of GNFs upon dynamic deformation. Compared with GNFs in un-deformed composites (Figure 4), those in impacted ones are obviously elongated, along with the macroscopic expansion of materials in lateral direction, i.e. the aspect ratio has increased upon impact deformation. This suggests an increase in the value of pr, and hence results in an enhanced load transfer, as indicated by Eq 3.
Microstructural analysis was employed to investigate the mechanisms concerning weakened strain rate hardening, as demonstrated by Figure 2. Figure 6 is a representative SEM image of the impacted specimen. Cracks are clearly observed and EDX analysis implies that the damaged phase is silicon carbide, which has been widely used as reinforcements [27,28,29]. Although it is effective in enhancing material strength, the brittle nature also brings about reduction in material strength, particularly at relatively large strains and high strain rates.
The aforementioned mechanism associate with cracking of silicon carbon can also been inferred from hardness tests of unreinforced and GNFs-reinforced Al before and after deformation. Figure 7a shows the changes in hardness of unreinforced Al after deformed to fracture, and demonstrates that plastic deformation does not lead to an increase in hardness as it takes place for conventional metallic materials due to generation and storage of dislocations during deformation [22,23], because micro-cracks within deformed material results in a decline in strength, which cancels out the enhancing effects arising from dislocation accumulation. This suggests that micro-cracking is a significant effect leading to decrease of material strength. As for GNFs-reinforced Al, such weakening effect is more pronounced as indicated by Figure 7a, with material hardness decreasing dramatically after deformation, because cracking of silicon carbide in GNFs-reinforced composites occurs at relative low strains in comparison with ductile Al matrix and promotes the drop in material strength. Figure 7b depicts the morphology of fracture surfaces for GNFs-reinforced composites deformed to fracture. The fracture of silicon carbide is evident and shows a feature distinct from that for the matrix.
Strain rate sensitivity of materials is usually represented by the exponent m in a power law relationship as shown in Eq 4 [30], where σ and ${\dot \varepsilon }$ denote respectively flow stress and strain rate, and σ0 is the reference flow stress at strain rate of ${{\dot \varepsilon }_0}$. Taking quasi-static test as the reference strain rate and using yield strength in Figure 2 as the flow stress, a linear line is fitted to the scattered data in Figure 8 and the values of m are determined as 0.08 and 0.03 respectively for unreinforced and GNFs-reinforced Al, which are in the same order of magnitude as that for coarse-grained metals [31,32]. The drop in m value due to addition of GNFs reflects the inhomogeneity of material microstructure and deformation that could not provide enough resistance to softening mechanism like localized deformation and is presumably due to the decrease in grain size, caused by involvement of reinforcements as grain refiner, that helps to activate the mechanism of cutting forest dislocations associate with the operation of Peierls barriers [33].
$ {\rm{ \mathsf{ σ} }} = {\sigma _0}{\left( {\frac{{\dot \varepsilon }}{{{{\dot \varepsilon }_0}}}} \right)^m} $ | (4) |
The effect of strain rate is also manifested by a noticeable drop in flow stress, particularly at dynamic strain rates. Figure 9 depicts the variation of drop in flow stress (Dsd) with strain rate, which is calculated by Eq. 5, with σM and σsa representing respectively the maximum and saturated stress. The increase Δσd of with strain rate is mainly caused by two reasons. Firstly, the rise in strain rate results in a higher temperature rise due to the conversion of plastic work into heat [22,23,24,] and hence softens materials in a greater degree. Secondly, nucleation and propagation of cracks in silicon carbide is strain rate dependent [34], and higher strain rate causes more severe stress concentration at the tip of cracks that accelerates the propagation of cracks, leading to a larger drop in stress. However, the maximum flow stress remains larger for higher strain rates, as shown in Figure 9, because shorter duration of deformation process indicates a higher rates of crack nucleation that requires greater stress to accomplish [35].
The effect of strain rate is also manifested by a noticeable drop in flow stress, particularly at dynamic strain rates. Figure 9 depicts the variation of drop in flow stress (Dsd) with strain rate, which is calculated by Eq. 5, with σM and σsa representing respectively the maximum and saturated stress. The increase Δσd of with strain rate is mainly caused by two reasons. Firstly, the rise in strain rate results in a higher temperature rise due to the conversion of plastic work into heat [22,23,24,] and hence softens materials in a greater degree. Secondly, nucleation and propagation of cracks in silicon carbide is strain rate dependent [34], and higher strain rate causes more severe stress concentration at the tip of cracks that accelerates the propagation of cracks, leading to a larger drop in stress. However, the maximum flow stress remains larger for higher strain rates, as shown in Figure 9, because shorter duration of deformation process indicates a higher rates of crack nucleation that requires greater stress to accomplish [35].
The effect of strain rate is also manifested by a noticeable drop in flow stress, particularly at dynamic strain rates. Figure 9 depicts the variation of drop in flow stress (Dsd) with strain rate, which is calculated by Eq. 5, with σM and σsa representing respectively the maximum and saturated stress. The increase Δσd of with strain rate is mainly caused by two reasons. Firstly, the rise in strain rate results in a higher temperature rise due to the conversion of plastic work into heat [22,23,24,] and hence softens materials in a greater degree. Secondly, nucleation and propagation of cracks in silicon carbide is strain rate dependent [34], and higher strain rate causes more severe stress concentration at the tip of cracks that accelerates the propagation of cracks, leading to a larger drop in stress. However, the maximum flow stress remains larger for higher strain rates, as shown in Figure 9, because shorter duration of deformation process indicates a higher rates of crack nucleation that requires greater stress to accomplish [35].
$ \Delta {{\rm{ \mathsf{ σ} }}_d} = {{\rm{ \mathsf{ σ} }}_M} - {{\rm{ \mathsf{ σ} }}_{sa}} $ | (5) |
Aluminum (Al) matrix composites containing graphene nanoflakes (GNFs) and silicon carbide was synthesized by a processing approach combining hot isostatic pressing, hot extrusion with heat treatment. Compared with unreinforced aluminum, GNFs-added composites possessed yield strength around three times higher upon quasi-static loading, and the yield strength at dynamic strain rates was elevated by more than 300MPa. Transfer of load from Al matrix to GNFs was considered the main mechanism accounting for improved strength for GNFs-reinforced composites. On the other hand, decreased strain hardening rate and declined strain rate sensitivity were resulted, and cracking of silicon carbide and its propagation was the underlying reason, although it helped to enhance the composites. Despite the drop of flow stress particularly at dynamic strain rates, the maximum flow stress of composites remained exhibiting an upward trend with the increase in strain rate, because nucleation of micro-cracks was strain rate dependent and required greater stress at higher strain rates.
The authors are grateful to the support from the National Natural Science Foundation of China (Grant No.: 51701197).
[1] | McNeal JE (1981) The zonal anatomy of the prostate. Prostate 2: 35-49. |
[2] |
Mcneal JE (1988) Normal Histology of the Prostate. Am J Surg Pathol 12: 619-633. doi: 10.1097/00000478-198808000-00003
![]() |
[3] | Isaacs JT (1994) Etiology of benign prostatic hyperplasia. Eur Urol 25 Suppl 1: 6-9. |
[4] | McNeal JE (1978) Origin and evolution of benign prostatic enlargement. Invest Urol 15: 340-345. |
[5] | Berry SJ, Coffey DS, Walsh PC, et al. (1984) The development of human benign prostatic hyperplasia with age. J Urol 132: 474-479. |
[6] |
Briganti A, Capitanio U, Suardi N, et al. (2009) Benign Prostatic Hyperplasia and Its Aetiologies. Eur Urol Suppl 8: 865-871. doi: 10.1016/j.eursup.2009.11.002
![]() |
[7] |
Ferlay J, Soerjomataram I, Dikshit R, et al. (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136: E359-386. doi: 10.1002/ijc.29210
![]() |
[8] | Cancer Research UK (2013) Prostate cancer statistics. |
[9] |
Nowell PC (1976) The clonal evolution of tumor cell populations. Science 194: 23-28. doi: 10.1126/science.959840
![]() |
[10] |
Collins AT, Berry PA, Hyde C, et al. (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65: 10946-10951. doi: 10.1158/0008-5472.CAN-05-2018
![]() |
[11] |
Visvader JE, Lindeman GJ (2012) Cancer stem cells: current status and evolving complexities. Cell Stem Cell 10: 717-728. doi: 10.1016/j.stem.2012.05.007
![]() |
[12] |
Ablin RJ, Soanes WA, Bronson P, et al. (1970) Precipitating antigens of the normal human prostate. J Reprod Fertil 22: 573-574. doi: 10.1530/jrf.0.0220573
![]() |
[13] | Papsidero LD, Wang MC, Valenzuela LA, et al. (1980) A prostate antigen in sera of prostatic cancer patients. Cancer Res 40: 2428-2432. |
[14] |
Nadler RB, Humphrey PA, Smith DS, et al. (1995) Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 154: 407-413. doi: 10.1016/S0022-5347(01)67064-2
![]() |
[15] |
Romero Otero J, Garcia Gomez B, Campos Juanatey F, et al. (2014) Prostate cancer biomarkers: an update. Urol Oncol 32: 252-260. doi: 10.1016/j.urolonc.2013.09.017
![]() |
[16] |
Gilgunn S, Conroy PJ, Saldova R, et al. (2013) Aberrant PSA glycosylation--a sweet predictor of prostate cancer. Nat Rev Urol 10: 99-107. doi: 10.1038/nrurol.2012.258
![]() |
[17] |
Hessels D, Klein Gunnewiek JM, van Oort I, et al. (2003) DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 44: 8-15. doi: 10.1016/S0302-2838(03)00201-X
![]() |
[18] |
Attard G, Clark J, Ambroisine L, et al. (2008) Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 27: 253-263. doi: 10.1038/sj.onc.1210640
![]() |
[19] | Gleason DF, Mellinger GT (1974) Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111: 58-64. |
[20] | Mellinger GT, Gleason D, Bailar J 3rd (1967) The histology and prognosis of prostatic cancer. J Urol 97: 331-337. |
[21] |
Conn PM, Crowley WF Jr. (1994) Gonadotropin-releasing hormone and its analogs. Annu Rev Med 45: 391-405. doi: 10.1146/annurev.med.45.1.391
![]() |
[22] |
Lubahn DB, Joseph DR, Sullivan PM, et al. (1988) Cloning of human androgen receptor complementary DNA and localization to the X chromosome. Science 240: 327-330. doi: 10.1126/science.3353727
![]() |
[23] |
Gelmann EP (2002) Molecular biology of the androgen receptor. J Clin Oncol 20: 3001-3015. doi: 10.1200/JCO.2002.10.018
![]() |
[24] |
Edwards A, Hammond HA, Jin L, et al. (1992) Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups. Genomics 12: 241-253. doi: 10.1016/0888-7543(92)90371-X
![]() |
[25] |
Verrijdt G, Haelens A, Claessens F (2003) Selective DNA recognition by the androgen receptor as a mechanism for hormone-specific regulation of gene expression. Mol Genet Metab 78: 175-185. doi: 10.1016/S1096-7192(03)00003-9
![]() |
[26] |
Maitland NJ, Frame FM, Polson ES, et al. (2011) Prostate cancer stem cells: do they have a basal or luminal phenotype? Horm Cancer 2: 47-61. doi: 10.1007/s12672-010-0058-y
![]() |
[27] |
Mirosevich J, Bentel JM, Zeps N, et al. (1999) Androgen receptor expression of proliferating basal and luminal cells in adult murine ventral prostate. J Endocrinol 162: 341-350. doi: 10.1677/joe.0.1620341
![]() |
[28] |
Radmayr C, Lunacek A, Schwentner C, et al. (2008) 5-alpha-reductase and the development of the human prostate. Indian J Urol 24: 309-312. doi: 10.4103/0970-1591.42610
![]() |
[29] |
Saartok T, Dahlberg E, Gustafsson JA (1984) Relative binding affinity of anabolic-androgenic steroids: comparison of the binding to the androgen receptors in skeletal muscle and in prostate, as well as to sex hormone-binding globulin. Endocrinology 114: 2100-2106. doi: 10.1210/endo-114-6-2100
![]() |
[30] |
Cano LQ, Lavery DN, Bevan CL (2013) Mini-review: Foldosome regulation of androgen receptor action in prostate cancer. Mol Cell Endocrinol 369: 52-62. doi: 10.1016/j.mce.2013.01.023
![]() |
[31] |
He B, Kemppainen JA, Voegel JJ, et al. (1999) Activation function 2 in the human androgen receptor ligand binding domain mediates interdomain communication with the NH(2)-terminal domain. J Biol Chem 274: 37219-37225. doi: 10.1074/jbc.274.52.37219
![]() |
[32] |
Massie CE, Lynch A, Ramos-Montoya A, et al. (2011) The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J 30: 2719-2733. doi: 10.1038/emboj.2011.158
![]() |
[33] |
Cleutjens KB, van Eekelen CC, van der Korput HA, et al. (1996) Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J Biol Chem 271: 6379-6388. doi: 10.1074/jbc.271.11.6379
![]() |
[34] |
Sun M, Yang L, Feldman RI, et al. (2003) Activation of phosphatidylinositol 3-kinase/Akt pathway by androgen through interaction of p85alpha, androgen receptor, and Src. J Biol Chem 278: 42992-43000. doi: 10.1074/jbc.M306295200
![]() |
[35] | Migliaccio A, Castoria G, Di Domenico M, et al. (2000) Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. EMBO J 19: 5406-5417. |
[36] | Liao RS, Ma S, Miao L, et al. (2013) Androgen receptor-mediated non-genomic regulation of prostate cancer cell proliferation. Transl Androl Urol 2: 187-196. |
[37] |
Peterziel H, Mink S, Schonert A, et al. (1999) Rapid signalling by androgen receptor in prostate cancer cells. Oncogene 18: 6322-6329. doi: 10.1038/sj.onc.1203032
![]() |
[38] |
Huggins C, Hodges CV (1972) Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 22: 232-240. doi: 10.3322/canjclin.22.4.232
![]() |
[39] |
Harris WP, Mostaghel EA, Nelson PS, et al. (2009) Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 6: 76-85. doi: 10.1038/ncpuro1296
![]() |
[40] |
Klugo RC, Farah RN, Cerny JC (1981) Bilateral orchiectomy for carcinoma of prostate. Response of serum testosterone and clinical response to subsequent estrogen therapy. Urology 17: 49-50. doi: 10.1016/0090-4295(81)90011-X
![]() |
[41] |
Labrie F, Dupont A, Belanger A, et al. (1986) Treatment of prostate cancer with gonadotropin-releasing hormone agonists. Endocr Rev 7: 67-74. doi: 10.1210/edrv-7-1-67
![]() |
[42] | Labrie F, Belanger A, Dupont A, et al. (1993) Science behind total androgen blockade: from gene to combination therapy. Clin Invest Med 16: 475-492. |
[43] |
Karantanos T, Corn PG, Thompson TC (2013) Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene 32: 5501-5511. doi: 10.1038/onc.2013.206
![]() |
[44] |
de Bono JS, Logothetis CJ, Molina A, et al. (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364: 1995-2005. doi: 10.1056/NEJMoa1014618
![]() |
[45] |
Tran C, Ouk S, Clegg NJ, et al. (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324: 787-790. doi: 10.1126/science.1168175
![]() |
[46] |
Kluetz PG, Pierce W, Maher VE, et al. (2014) Radium Ra 223 dichloride injection: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res 20: 9-14. doi: 10.1158/1078-0432.CCR-13-2665
![]() |
[47] |
Pal S, Gupta R, Davuluri RV (2012) Alternative transcription and alternative splicing in cancer. Pharmacol Ther 136: 283-294. doi: 10.1016/j.pharmthera.2012.08.005
![]() |
[48] |
Heuze-Vourc'h N, Leblond V, Courty Y (2003) Complex alternative splicing of the hKLK3 gene coding for the tumor marker PSA (prostate-specific-antigen). Eur J Biochem 270: 706-714. doi: 10.1046/j.1432-1033.2003.03425.x
![]() |
[49] |
Narla G, DiFeo A, Fernandez Y, et al. (2008) KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis. J Clin Invest 118: 2711-2721. doi: 10.1172/JCI34780
![]() |
[50] |
Thorsen K, Sorensen KD, Brems-Eskildsen AS, et al. (2008) Alternative splicing in colon, bladder, and prostate cancer identified by exon array analysis. Mol Cell Proteomics 7: 1214-1224. doi: 10.1074/mcp.M700590-MCP200
![]() |
[51] | Erho N, Buerki C, Triche TJ, et al. (2012) Transcriptome-wide detection of differentially expressed coding and non-coding transcripts and their clinical significance in prostate cancer. J Oncol 2012: 541353. |
[52] |
Rajan P, Dalgliesh C, Carling PJ, et al. (2011) Identification of novel androgen-regulated pathways and mRNA isoforms through genome-wide exon-specific profiling of the LNCaP transcriptome. PLoS One 6: e29088. doi: 10.1371/journal.pone.0029088
![]() |
[53] | Munkley J, Rajan P, Lafferty NP, et al. (2014) A novel androgen-regulated isoform of the TSC2 tumour suppressor gene increases cell proliferation. Oncotarget 5: 131-139. |
[54] |
Busa R, Paronetto MP, Farini D, et al. (2007) The RNA-binding protein Sam68 contributes to proliferation and survival of human prostate cancer cells. Oncogene 26: 4372-4382. doi: 10.1038/sj.onc.1210224
![]() |
[55] |
Rajan P, Gaughan L, Dalgliesh C, et al. (2008) The RNA-binding and adaptor protein Sam68 modulates signal-dependent splicing and transcriptional activity of the androgen receptor. J Pathol 215: 67-77. doi: 10.1002/path.2324
![]() |
[56] | Mavrou A, Brakspear K, Hamdollah-Zadeh M, et al. (2014) Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer. Oncogene 34: 4311-4319. |
[57] |
Clark EL, Coulson A, Dalgliesh C, et al. (2008) The RNA helicase p68 is a novel androgen receptor coactivator involved in splicing and is overexpressed in prostate cancer. Cancer Res 68: 7938-7946. doi: 10.1158/0008-5472.CAN-08-0932
![]() |
[58] | Wu X, Daniels G, Lee P, et al. (2014) Lipid metabolism in prostate cancer. Am J Clin Exp Urol 2: 111-120. |
[59] |
Suburu J, Chen YQ (2012) Lipids and prostate cancer. Prostaglandins Other Lipid Mediat 98: 1-10. doi: 10.1016/j.prostaglandins.2012.03.003
![]() |
[60] |
Swinnen JV, Ulrix W, Heyns W, et al. (1997) Coordinate regulation of lipogenic gene expression by androgens: evidence for a cascade mechanism involving sterol regulatory element binding proteins. Proc Natl Acad Sci U S A 94: 12975-12980. doi: 10.1073/pnas.94.24.12975
![]() |
[61] | Swinnen JV, Esquenet M, Goossens K, et al. (1997) Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP. Cancer Res 57: 1086-1090. |
[62] | Swinnen JV, Vanderhoydonc F, Elgamal AA, et al. (2000) Selective activation of the fatty acid synthesis pathway in human prostate cancer. Int J Cancer 88: 176-179. |
[63] |
Liu Y (2006) Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate Cancer Prostatic Dis 9: 230-234. doi: 10.1038/sj.pcan.4500879
![]() |
[64] |
Segawa T, Nau ME, Xu LL, et al. (2002) Androgen-induced expression of endoplasmic reticulum (ER) stress response genes in prostate cancer cells. Oncogene 21: 8749-8758. doi: 10.1038/sj.onc.1205992
![]() |
[65] |
Sheng X, Arnoldussen YJ, Storm M, et al. (2015) Divergent androgen regulation of unfolded protein response pathways drives prostate cancer. EMBO Mol Med 7: 788-801. doi: 10.15252/emmm.201404509
![]() |
[66] | Munkley J, Mills IG, Elliott DJ (2016) The role of glycans in the development and progression of prostate cancer. Nat Rev Urol 13: 324-333. |
[67] | Hakomori S (1996) Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res 56: 5309-5318. |
[68] |
Reis CA, Osorio H, Silva L, et al. (2010) Alterations in glycosylation as biomarkers for cancer detection. J Clin Pathol 63: 322-329. doi: 10.1136/jcp.2009.071035
![]() |
[69] |
Pinho SS, Reis CA (2015) Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer 15: 540-555. doi: 10.1038/nrc3982
![]() |
[70] |
Barfeld SJ, East P, Zuber V, et al. (2014) Meta-analysis of prostate cancer gene expression data identifies a novel discriminatory signature enriched for glycosylating enzymes. BMC Med Genom 7: 513. doi: 10.1186/s12920-014-0074-9
![]() |
[71] | Munkley J, Elliott DJ (2016) Hallmarks of glycosylation in cancer. Oncotarget in press. |
[72] | Munkley J, Vodak D, Livermore KE, et al. (2016) Glycosylation is an androgen-regulated process essential for prostate cancer cell viability. EBioMedicine in press. |
[73] |
Itkonen HM, Engedal N, Babaie E, et al. (2015) UAP1 is overexpressed in prostate cancer and is protective against inhibitors of N-linked glycosylation. Oncogene 34: 3744-3750. doi: 10.1038/onc.2014.307
![]() |
[74] | Munkley J, Oltean S, Vodak D, et al. (2015) The androgen receptor controls expression of the cancer-associated sTn antigen and cell adhesion through induction of ST6GalNAc1 in prostate cancer. Oncotarget 6: 34358-34374. |
[75] |
Sato T, Yoneyama T, Tobisawa Y, et al. (2016) Core 2 (beta-1, 6-N-acetylglucosaminyltransferase-1 expression in prostate biopsy specimen is an indicator of prostate cancer aggressiveness. Biochem Biophys Res Commun 470: 150-156. doi: 10.1016/j.bbrc.2016.01.011
![]() |
[76] |
Chen Z, Gulzar ZG, St Hill CA, et al. (2014) Increased expression of GCNT1 is associated with altered O-glycosylation of PSA, PAP, and MUC1 in human prostate cancers. Prostate 74: 1059-1067. doi: 10.1002/pros.22826
![]() |
[77] |
Taylor BS, Schultz N, Hieronymus H, et al. (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18: 11-22. doi: 10.1016/j.ccr.2010.05.026
![]() |
[78] | Pourmand G, Ziaee AA, Abedi AR, et al. (2007) Role of PTEN gene in progression of prostate cancer. Urol J 4: 95-100. |
[79] |
Robinson D, Van Allen EM, Wu YM, et al. (2015) Integrative clinical genomics of advanced prostate cancer. Cell 161: 1215-1228. doi: 10.1016/j.cell.2015.05.001
![]() |
[80] |
Carver BS, Chapinski C, Wongvipat J, et al. (2011) Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19: 575-586. doi: 10.1016/j.ccr.2011.04.008
![]() |
[81] |
Munkley J, Lafferty NP, Kalna G, et al. (2015) Androgen-regulation of the protein tyrosine phosphatase PTPRR activates ERK1/2 signalling in prostate cancer cells. BMC Cancer 15: 9. doi: 10.1186/s12885-015-1012-8
![]() |
[82] |
Schutzman JL, Martin GR (2012) Sprouty genes function in suppression of prostate tumorigenesis. Proc Natl Acad Sci U S A 109: 20023-20028. doi: 10.1073/pnas.1217204109
![]() |
[83] | Yokoyama NN, Shao S, Hoang BH, et al. (2014) Wnt signaling in castration-resistant prostate cancer: implications for therapy. Am J Clin Exp Urol 2: 27-44. |
[84] | Truica CI, Byers S, Gelmann EP (2000) Beta-catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res 60: 4709-4713. |
[85] |
Mulholland DJ, Cheng H, Reid K, et al. (2002) The androgen receptor can promote beta-catenin nuclear translocation independently of adenomatous polyposis coli. J Biol Chem 277: 17933-17943. doi: 10.1074/jbc.M200135200
![]() |
[86] |
Rajan P, Sudbery IM, Villasevil ME, et al. (2014) Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy. Eur Urol 66: 32-39. doi: 10.1016/j.eururo.2013.08.011
![]() |
[87] |
Chen G, Shukeir N, Potti A, et al. (2004) Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer 101: 1345-1356. doi: 10.1002/cncr.20518
![]() |
[88] | Voeller HJ, Truica CI, Gelmann EP (1998) Beta-catenin mutations in human prostate cancer. Cancer Res 58: 2520-2523. |
[89] |
Mostaghel EA, Solomon KR, Pelton K, et al. (2012) Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors. PLoS One 7: e30062. doi: 10.1371/journal.pone.0030062
![]() |
[90] | Hamid AR, Pfeiffer MJ, Verhaegh GW, et al. (2012) Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer. Mol Med 18: 1449-1455. |
[91] |
Stanbrough M, Bubley GJ, Ross K, et al. (2006) Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66: 2815-2825. doi: 10.1158/0008-5472.CAN-05-4000
![]() |
[92] |
Mohler JL, Gregory CW, Ford OH, 3rd, et al. (2004) The androgen axis in recurrent prostate cancer. Clin Cancer Res 10: 440-448. doi: 10.1158/1078-0432.CCR-1146-03
![]() |
[93] |
Knuuttila M, Yatkin E, Kallio J, et al. (2014) Castration induces up-regulation of intratumoral androgen biosynthesis and androgen receptor expression in an orthotopic VCaP human prostate cancer xenograft model. Am J Pathol 184: 2163-2173. doi: 10.1016/j.ajpath.2014.04.010
![]() |
[94] |
Liu W, Xie CC, Zhu Y, et al. (2008) Homozygous deletions and recurrent amplifications implicate new genes involved in prostate cancer. Neoplasia 10: 897-907. doi: 10.1593/neo.08428
![]() |
[95] |
Edwards J, Krishna NS, Grigor KM, et al. (2003) Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 89: 552-556. doi: 10.1038/sj.bjc.6601127
![]() |
[96] | Edwards J, Krishna NS, Witton CJ, et al. (2003) Gene amplifications associated with the development of hormone-resistant prostate cancer. Clin Cancer Res 9: 5271-5281. |
[97] |
Holzbeierlein J, Lal P, LaTulippe E, et al. (2004) Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 164: 217-227. doi: 10.1016/S0002-9440(10)63112-4
![]() |
[98] |
Barbieri CE, Bangma CH, Bjartell A, et al. (2013) The mutational landscape of prostate cancer. Eur Urol 64: 567-576. doi: 10.1016/j.eururo.2013.05.029
![]() |
[99] |
Grasso CS, Wu YM, Robinson DR, et al. (2012) The mutational landscape of lethal castration-resistant prostate cancer. Nature 487: 239-243. doi: 10.1038/nature11125
![]() |
[100] |
Shaffer DR, Leversha MA, Danila DC, et al. (2007) Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res 13: 2023-2029. doi: 10.1158/1078-0432.CCR-06-2701
![]() |
[101] |
Salvi S, Casadio V, Conteduca V, et al. (2015) Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone. Br J Cancer 112: 1717-1724. doi: 10.1038/bjc.2015.128
![]() |
[102] |
Azad AA, Volik SV, Wyatt AW, et al. (2015) Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer. Clin Cancer Res 21: 2315-2324. doi: 10.1158/1078-0432.CCR-14-2666
![]() |
[103] |
Attard G, Swennenhuis JF, Olmos D, et al. (2009) Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 69: 2912-2918. doi: 10.1158/0008-5472.CAN-08-3667
![]() |
[104] | Wallen MJ, Linja M, Kaartinen K, et al. (1999) Androgen receptor gene mutations in hormone-refractory prostate cancer. J Pathol 189: 559-563. |
[105] |
Gottlieb B, Beitel LK, Nadarajah A, et al. (2012) The androgen receptor gene mutations database: 2012 update. Hum Mutat 33: 887-894. doi: 10.1002/humu.22046
![]() |
[106] | Gaddipati JP, McLeod DG, Heidenberg HB, et al. (1994) Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res 54: 2861-2864. |
[107] |
Steketee K, Timmerman L, Ziel-van der Made AC, et al. (2002) Broadened ligand responsiveness of androgen receptor mutants obtained by random amino acid substitution of H874 and mutation hot spot T877 in prostate cancer. Int J Cancer 100: 309-317. doi: 10.1002/ijc.10495
![]() |
[108] |
Steinkamp MP, O'Mahony OA, Brogley M, et al. (2009) Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. Cancer Res 69: 4434-4442. doi: 10.1158/0008-5472.CAN-08-3605
![]() |
[109] | Hu R, Dunn TA, Wei S, et al. (2009) Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 69: 16-22. |
[110] |
Sun S, Sprenger CC, Vessella RL, et al. (2010) Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 120: 2715-2730. doi: 10.1172/JCI41824
![]() |
[111] |
Hu R, Lu C, Mostaghel EA, et al. (2012) Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res 72: 3457-3462. doi: 10.1158/0008-5472.CAN-11-3892
![]() |
[112] |
Li Y, Chan SC, Brand LJ, et al. (2013) Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res 73: 483-489. doi: 10.1158/0008-5472.CAN-12-3630
![]() |
[113] |
Hornberg E, Ylitalo EB, Crnalic S, et al. (2011) Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS One 6: e19059. doi: 10.1371/journal.pone.0019059
![]() |
[114] |
Antonarakis ES, Lu C, Wang H, et al. (2014) AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371: 1028-1038. doi: 10.1056/NEJMoa1315815
![]() |
[115] | Steinestel J, Luedeke M, Arndt A, et al. (2015) Detecting predictive androgen receptor modifications in circulating prostate cancer cells. Oncotarget 5. |
[116] |
Culig Z (2016) Androgen Receptor Coactivators in Regulation of Growth and Differentiation in Prostate Cancer. J Cell Physiol 231: 270-274. doi: 10.1002/jcp.25099
![]() |
[117] |
Heemers HV, Sebo TJ, Debes JD, et al. (2007) Androgen deprivation increases p300 expression in prostate cancer cells. Cancer Res 67: 3422-3430. doi: 10.1158/0008-5472.CAN-06-2836
![]() |
[118] |
Comuzzi B, Nemes C, Schmidt S, et al. (2004) The androgen receptor co-activator CBP is up-regulated following androgen withdrawal and is highly expressed in advanced prostate cancer. J Pathol 204: 159-166. doi: 10.1002/path.1609
![]() |
[119] |
Halkidou K, Gnanapragasam VJ, Mehta PB, et al. (2003) Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene 22: 2466-2477. doi: 10.1038/sj.onc.1206342
![]() |
[120] | Debes JD, Schmidt LJ, Huang H, et al. (2002) p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. Cancer Res 62: 5632-5636. |
[121] | Shiota M, Yokomizo A, Masubuchi D, et al. (2010) Tip60 Promotes Prostate Cancer Cell Proliferation by Translocation of Androgen Receptor into the Nucleus. Prostate 70: 540-554. |
[122] | Kishimoto T (1989) The biology of interleukin-6. Blood 74: 1-10. |
[123] |
Okamoto M, Lee C, Oyasu R (1997) Autocrine effect of androgen on proliferation of an androgen responsive prostatic carcinoma cell line, LNCAP: role of interleukin-6. Endocrinology 138: 5071-5074. doi: 10.1210/endo.138.11.5653
![]() |
[124] | Hobisch A, Rogatsch H, Hittmair A, et al. (2000) Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue. J Pathol 191: 239-244. |
[125] |
Culig Z, Bartsch G, Hobisch A (2002) Interleukin-6 regulates androgen receptor activity and prostate cancer cell growth. Mol Cell Endocrinol 197: 231-238. doi: 10.1016/S0303-7207(02)00263-0
![]() |
[126] |
Twillie DA, Eisenberger MA, Carducci MA, et al. (1995) Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology 45: 542-549. doi: 10.1016/S0090-4295(99)80034-X
![]() |
[127] | Chen T, Wang LH, Farrar WL (2000) Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Cancer Res 60: 2132-2135. |
[128] |
Heinrich PC, Behrmann I, Haan S, et al. (2003) Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374: 1-20. doi: 10.1042/bj20030407
![]() |
[129] | Olayioye MA, Neve RM, Lane HA, et al. (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19: 3159-3167. |
[130] |
Slamon DJ, Godolphin W, Jones LA, et al. (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712. doi: 10.1126/science.2470152
![]() |
[131] | Signoretti S, Montironi R, Manola J, et al. (2000) Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 92: 1918-1925. |
[132] | Wen Y, Hu MC, Makino K, et al. (2000) HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 60: 6841-6845. |
[133] |
Karin M (2006) Nuclear factor-kappaB in cancer development and progression. Nature 441: 431-436. doi: 10.1038/nature04870
![]() |
[134] |
Suh J, Payvandi F, Edelstein LC, et al. (2002) Mechanisms of constitutive NF-kappaB activation in human prostate cancer cells. Prostate 52: 183-200. doi: 10.1002/pros.10082
![]() |
[135] |
Zhang L, Altuwaijri S, Deng F, et al. (2009) NF-kappaB regulates androgen receptor expression and prostate cancer growth. Am J Pathol 175: 489-499. doi: 10.2353/ajpath.2009.080727
![]() |
[136] |
Nadiminty N, Lou W, Sun M, et al. (2010) Aberrant activation of the androgen receptor by NF-kappaB2/p52 in prostate cancer cells. Cancer Res 70: 3309-3319. doi: 10.1158/0008-5472.CAN-09-3703
![]() |
[137] |
Krijnen JL, Janssen PJ, Ruizeveld de Winter JA, et al. (1993) Do neuroendocrine cells in human prostate cancer express androgen receptor? Histochemistry 100: 393-398. doi: 10.1007/BF00268938
![]() |
[138] |
Bonkhoff H, Stein U, Remberger K (1995) Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells. Hum Pathol 26: 167-170. doi: 10.1016/0046-8177(95)90033-0
![]() |
[139] | Li Q, Zhang CS, Zhang Y (2016) Molecular aspects of prostate cancer with neuroendocrine differentiation. Chin J Cancer Res 28: 122-129. |
[140] | Alberti C (2010) Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features. G Chir 31: 568-574. |
[141] |
Yuan TC, Veeramani S, Lin FF, et al. (2006) Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells. Endocr Relat Cancer 13: 151-167. doi: 10.1677/erc.1.01043
![]() |
[142] |
Jongsma J, Oomen MH, Noordzij MA, et al. (1999) Kinetics of neuroendocrine differentiation in an androgen-dependent human prostate xenograft model. Am J Pathol 154: 543-551. doi: 10.1016/S0002-9440(10)65300-X
![]() |
[143] |
Hirano D, Okada Y, Minei S, et al. (2004) Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol 45: 586-592. doi: 10.1016/j.eururo.2003.11.032
![]() |
[144] |
Sagnak L, Topaloglu H, Ozok U, et al. (2011) Prognostic significance of neuroendocrine differentiation in prostate adenocarcinoma. Clin Genitourin Cancer 9: 73-80. doi: 10.1016/j.clgc.2011.07.003
![]() |
[145] |
Qiu Y, Robinson D, Pretlow TG, et al. (1998) Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3'-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells. Proc Natl Acad Sci U S A 95: 3644-3649. doi: 10.1073/pnas.95.7.3644
![]() |
[146] | Spiotto MT, Chung TD (2000) STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells. Prostate 42: 186-195. |
[147] | Moritz T, Venz S, Junker H, et al. (2016) Isoform 1 of TPD52 (PC-1) promotes neuroendocrine transdifferentiation in prostate cancer cells. Tumour Biol in press. |
[148] | Gururajan M, Cavassani KA, Sievert M, et al. (2015) SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer. Oncotarget 6: 44072-44083. |
[149] |
Uysal-Onganer P, Kawano Y, Caro M, et al. (2010) Wnt-11 promotes neuroendocrine-like differentiation, survival and migration of prostate cancer cells. Mol Cancer 9: 55. doi: 10.1186/1476-4598-9-55
![]() |
[150] | Wu C, Huang J (2007) Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway is essential for neuroendocrine differentiation of prostate cancer. J Biol Chem 282: 3571-3583. |
[151] |
Kowalska K, Piastowska-Ciesielska AW (2016) Oestrogens and oestrogen receptors in prostate cancer. Springerplus 5: 522. doi: 10.1186/s40064-016-2185-6
![]() |
[152] |
Thompson VC, Morris TG, Cochrane DR, et al. (2006) Relaxin becomes upregulated during prostate cancer progression to androgen independence and is negatively regulated by androgens. Prostate 66: 1698-1709. doi: 10.1002/pros.20423
![]() |
[153] |
Liu S, Vinall RL, Tepper C, et al. (2008) Inappropriate activation of androgen receptor by relaxin via beta-catenin pathway. Oncogene 27: 499-505. doi: 10.1038/sj.onc.1210671
![]() |
[154] |
Yu S, Xia S, Yang D, et al. (2013) Androgen receptor in human prostate cancer-associated fibroblasts promotes prostate cancer epithelial cell growth and invasion. Med Oncol 30: 674. doi: 10.1007/s12032-013-0674-9
![]() |
[155] |
Roberts AB, Anzano MA, Wakefield LM, et al. (1985) Type beta transforming growth factor: a bifunctional regulator of cellular growth. Proc Natl Acad Sci U S A 82: 119-123. doi: 10.1073/pnas.82.1.119
![]() |
[156] |
Fuzio P, Ditonno P, Rutigliano M, et al. (2012) Regulation of TGF-beta1 expression by androgen deprivation therapy of prostate cancer. Cancer Lett 318: 135-144. doi: 10.1016/j.canlet.2011.08.034
![]() |
[157] |
Yang F, Tuxhorn JA, Ressler SJ, et al. (2005) Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis. Cancer Res 65: 8887-8895. doi: 10.1158/0008-5472.CAN-05-1702
![]() |
[158] |
Yang F, Chen Y, Shen T, et al. (2014) Stromal TGF-beta signaling induces AR activation in prostate cancer. Oncotarget 5: 10854-10869. doi: 10.18632/oncotarget.2536
![]() |
1. | Mahdi Hedayatian, Amir Momeni, Alireza Nezamabadi, Khodadad Vahedi, Effect of graphene oxide nanoplates on the microstructure, quasi-static and dynamic penetration behavior of Al6061 nanocomposites, 2020, 182, 13598368, 107652, 10.1016/j.compositesb.2019.107652 | |
2. | P. Lava Kumar, A. Lombardi, G. Byczynski, S.V.S. Narayana Murty, B.S. Murty, L. Bichler, Recent advances in aluminium matrix composites reinforced with graphene-based nanomaterial: A critical review, 2022, 128, 00796425, 100948, 10.1016/j.pmatsci.2022.100948 | |
3. | Awss A. Abdulrazaq, Saad R. Ahmed, Farouk M. Mahdi, Agricultural waste and natural dolomite for green production of aluminum composites, 2022, 11, 26667908, 100565, 10.1016/j.clet.2022.100565 | |
4. | Awss A. Abdulrazaq, Saad Ahmed, Farook M. Mahdi, Agricultural waste and natural dolomite for green production of aluminum composites, 2023, 12, 26667908, 100588, 10.1016/j.clet.2022.100588 |